The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review (Q90168426)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31534197%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

review article

3 references

3 July 2021

1 August 2022

The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31534197%20AND%20SRC:MED&resulttype=core&format=json

hematopoietic stem cell transplantation

11 April 2020

main subject

1 reference

stem cell transplantation

3 July 2021

1 reference

1 reference

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31534197%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Francesca Palandri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31534197%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Emanuela Sant'Antonio

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31534197%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Massimo Breccia

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31534197%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

Massimiliano Bonifacio

series ordinal

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31534197%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

publication date

18 September 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31534197%20AND%20SRC:MED&resulttype=core&format=json

Bone Marrow Transplantation

11 April 2020

1 April 2020

2 references

3 July 2021

1 August 2022

1 reference

inferred from page(s)

published in

3 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31534197%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

3 July 2021

1 August 2022

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31534197%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31534197%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

page(s)

708-716

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31534197%20AND%20SRC:MED&resulttype=core&format=json

Creative Commons Attribution

11 April 2020

2 references

3 July 2021

1 August 2022

0 references

The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Allogeneic Stem Cell Transplantation in Myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Allogeneic hematopoietic stem cell transplantation for myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Allogeneic stem-cell transplantation for myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Outcome Improvement After Allogeneic Stem-Cell Transplantation in Myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

One thousand patients with primary myelofibrosis: the mayo clinic experience

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Allogeneic Hematopoietic Stem-Cell Transplantation for Myelofibrosis: A Practical Review

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Mutations and prognosis in primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Post-ET and Post-PV Myelofibrosis: Updates on a Distinct Prognosis from Primary Myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Risk models predicting survival after reduced-intensity transplantation for myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Allogeneic stem cell transplantation after reduced-intensity conditioning in patients with myelofibrosis: a prospective, multicenter study of the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Safety and efficacy of ruxolitinib in an open-label, multicenter, single-arm phase 3b expanded-access study in patients with myelofibrosis: a snapshot of 1144 patients in the JUMP trial

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN international working group

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

The International Prognostic Scoring System does not accurately discriminate different risk categories in patients with post-essential thrombocythemia and post-polycythemia vera myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Performance of the myelofibrosis secondary to PV and ET-prognostic model (MYSEC-PM) in a series of 262 patients from the Spanish registry of myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Associations and prognostic interactions between circulating levels of hepcidin, ferritin and inflammatory cytokines in primary myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

MPD-RC 101 prospective study of reduced-intensity allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Outcome after Transplantation According to Reduced-Intensity Conditioning Regimen in Patients Undergoing Transplantation for Myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Impact of ruxolitinib pretreatment on outcomes after allogeneic stem cell transplantation in patients with myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Peritransplantation Ruxolitinib Prevents Acute Graft-versus-Host Disease in Patients with Myelofibrosis Undergoing Allogenic Stem Cell Transplantation

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Replacement of hematopoietic system by allogeneic stem cell transplantation in myelofibrosis patients induces rapid regression of bone marrow fibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Impact of JAK2V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Outcome of patients with Myelofibrosis relapsing after allogeneic stem cell transplant: a retrospective study by the Chronic Malignancies Working Party of EBMT

1 reference

https://api.crossref.org/works/10.1038%2FS41409-019-0683-1

7 January 2021

Splenectomy in myelofibrosis with myeloid metaplasia: a single-institution experience with 223 patients.

1 reference

12 December 2020

Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation.

1 reference

12 December 2020

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment

1 reference

12 December 2020

JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation

1 reference

12 December 2020

Allogeneic hemopoietic SCT for patients with primary myelofibrosis: a predictive transplant score based on transfusion requirement, spleen size and donor type

1 reference

12 December 2020

Outcome of transplantation for myelofibrosis

1 reference

12 December 2020

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).

1 reference

12 December 2020

The role of allogeneic SCT in primary myelofibrosis: a British Society for Blood and Marrow Transplantation study.

1 reference

12 December 2020

Red blood cell transfusion-dependency implies a poor survival in primary myelofibrosis irrespective of IPSS and DIPSS

1 reference

12 December 2020

Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients

1 reference

12 December 2020

DIPSS plus: a refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status

1 reference

12 December 2020

Janus kinase-2 inhibition induces durable tolerance to alloantigen by human dendritic cell-stimulated T cells yet preserves immunity to recall antigen

1 reference

12 December 2020

The Dynamic International Prognostic Scoring System for myelofibrosis predicts outcomes after hematopoietic cell transplantation

1 reference

12 December 2020

Prognostic impact of posttransplantation iron overload after allogeneic stem cell transplantation.

1 reference

12 December 2020

Allogeneic hematopoietic cell transplantation for myelofibrosis in patients pretreated with the JAK1 and JAK2 inhibitor ruxolitinib.

1 reference

12 December 2020

Prognostic effect of calreticulin mutations in patients with myelofibrosis after allogeneic hematopoietic stem cell transplantation

1 reference

12 December 2020

The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients

1 reference

12 December 2020

JAK inhibition with ruxolitinib as pretreatment for allogeneic stem cell transplantation in primary or post-ET/PV myelofibrosis.

1 reference

12 December 2020

Type 1 vs type 2 calreticulin mutations in primary myelofibrosis: differences in phenotype and prognostic impact.

1 reference

12 December 2020

Iron chelation therapy with deferasirox in the management of iron overload in primary myelofibrosis

1 reference

12 December 2020

Phase IV open-label study of the efficacy and safety of deferasirox after allogeneic stem cell transplantation

1 reference

12 December 2020

Hemoglobin levels and circulating blasts are two easily evaluable diagnostic parameters highly predictive of leukemic transformation in primary myelofibrosis

1 reference

12 December 2020

Chelation efficacy and erythroid response during deferasirox treatment in patients with myeloproliferative neoplasms in fibrotic phase

1 reference

12 December 2020

Efficacy and safety of deferasirox in non-thalassemic patients with elevated ferritin levels after allogeneic hematopoietic stem cell transplantation

1 reference

12 December 2020

Improved Outcome of Alternative Donor Transplantations in Patients with Myelofibrosis: From Unrelated to Haploidentical Family Donors.

1 reference

12 December 2020

Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis.

1 reference

12 December 2020

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.

1 reference

12 December 2020

The Impact of Splenectomy in Myelofibrosis Patients before Allogeneic Hematopoietic Stem Cell Transplantation

1 reference

12 December 2020

Impact of Molecular Genetics on Outcome in Myelofibrosis Patients after Allogeneic Stem Cell Transplantation

1 reference

12 December 2020

A clinical-molecular prognostic model to predict survival in patients with post polycythemia vera and post essential thrombocythemia myelofibrosis.

1 reference

12 December 2020

MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis

1 reference

12 December 2020

Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients.

1 reference

12 December 2020

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.

1 reference

12 December 2020

Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients

1 reference

12 December 2020

Family mismatched allogeneic stem cell transplantation for Myelofibrosis: Report from the Chronic Malignancies Working Party of EBMT

1 reference

12 December 2020

Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a lar

1 reference

12 December 2020

Busulfan- or Thiotepa-Based Conditioning in Myelofibrosis: A Phase II Multicenter Randomized Study from the GITMO Group

1 reference

12 December 2020

Long-term outcome after allogeneic hematopoietic cell transplantation for myelofibrosis

1 reference

12 December 2020

Comprehensive clinical-molecular transplant scoring system for myelofibrosis undergoing stem cell transplantation

1 reference

12 December 2020

Comparison of Outcomes of Allogeneic Transplantation for Primary Myelofibrosis among Hematopoietic Stem Cell Source Groups

1 reference

12 December 2020

Guidelines from the 2017 European Conference on Infections in Leukaemia for management of HHV-6 infection in patients with hematologic malignancies and after hematopoietic stem cell transplantation

1 reference

12 December 2020

10.1038/S41409-019-0683-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31534197%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31534197%20AND%20SRC:MED&resulttype=core&format=json

11 April 2020

PubMed publication ID

31534197

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:31534197%20AND%20SRC:MED&resulttype=core&format=json